An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions

Abstract

BRCA mutation-associated PAC represents an underidentified, but clinically important, subgroup of patients. This is of particular relevance given the ongoing development of therapeutic agents targeting DNA repair, which may potentially offer a significant benefit to a genetically selected population. We anticipate that further study and understanding of the clinical and biologic features of BRCA-mutant PAC will aid in the identification of tissue biomarkers indicating defective tumor DNA repair pathways in sporadic PAC.